| 3.26 0.11 (3.49%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.59 | 1-year : | 5.26 |
| Resists | First : | 3.93 | Second : | 4.5 |
| Pivot price | 3.56  |
|||
| Supports | First : | 3 | Second : | 2.5 |
| MAs | MA(5) : | 3.22 |
MA(20) : | 3.67 |
| MA(100) : | 3.24 |
MA(250) : | 6.63 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 17.4 |
D(3) : | 13.6 |
| RSI | RSI(14): 42.3 |
|||
| 52-week | High : | 16.63 | Low : | 2.19 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RCKT ] has closed above bottom band by 23.2%. Bollinger Bands are 51.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.29 - 3.31 | 3.31 - 3.33 |
| Low: | 3.05 - 3.08 | 3.08 - 3.1 |
| Close: | 3.22 - 3.26 | 3.26 - 3.29 |
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
Fri, 07 Nov 2025
Rocket Pharmaceuticals: Q3 Earnings Snapshot - theheraldreview.com
Thu, 06 Nov 2025
Rocket Pharmaceuticals, Inc. Q3 Loss Decreases, Beats Estimates - Nasdaq
Thu, 06 Nov 2025
Rocket Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary - TradingView
Thu, 06 Nov 2025
Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress - Business Wire
Thu, 06 Nov 2025
Rocket Pharmaceuticals: Q3 Earnings Snapshot - New Haven Register
Sun, 26 Oct 2025
Is Rocket Pharmaceuticals (RCKT) One of the Best NASDAQ Stocks Under $5 to Buy Now? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 108 (M) |
| Shares Float | 78 (M) |
| Held by Insiders | 3.6 (%) |
| Held by Institutions | 88.6 (%) |
| Shares Short | 12,400 (K) |
| Shares Short P.Month | 14,890 (K) |
| EPS | -2.51 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.27 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -38.1 % |
| Return on Equity (ttm) | -69.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.36 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -204 (M) |
| Levered Free Cash Flow | -101 (M) |
| PE Ratio | -1.3 |
| PEG Ratio | 0 |
| Price to Book value | 0.99 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.73 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|